BioSpace artwork

Life Sciences · BioSpace

BioSpace

by BioSpace

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Latest episodes

Showing 20 · updated from the feed

Can we finally get ahead of drug shortages?

In this episode of Denatured, you'll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cenco

Nov 12
20 min

Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November

Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warni

Nov 11
23 min

Beyond the needle: The future of intratumoral therapy

In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. W

Nov 5
21 min

Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review

The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another in

Nov 4
23 min

Stability, speed and strategy: Inside Australia’s early‑stage edge

In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Re

Oct 29
21 min

Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025

Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking pri

Oct 28
23 min

Why investors are taking another look at kidney disease

In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard ta

Oct 22
18 min

Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners

China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare dise

Oct 21
17 min

Bonus: Q3 2026 Job Market Update

BioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quart

Oct 20
16 min

The decisions behind scientific progress

In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, w

Oct 15
10 min

J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback

Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating i

Oct 14
19 min

Beyond equity: Why venture debt is reshaping European biotech

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys ti

Oct 8
22 min

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals

Oct 7
24 min

The race for access: How the FAIR Act could reclaim U.S. biotech leadership

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. pati

Oct 1
20 min

AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its

Sep 30
20 min

How radioligand therapy is rewriting cancer care

In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and

Sep 24
15 min

Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz

Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconv

Sep 23
21 min

When vision fades: Rethinking wet AMD and the durability gap

In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and

Sep 17
21 min

FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing th

Sep 16
22 min

The supply chain fault lines of modern pharma

In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we

Sep 10
36 min

Chart trend

Position in the Life Sciences chart (US), last 90 days.

#12
all-time peak
390
days in the top 50 since Nov 2024

Chart positions

Where BioSpace ranks today in each Apple Podcasts chart (US, Nov 17, 2026).

#47 ▲ 3 Life Sciences US

More podcasts like BioSpace

Popular shows in Life Sciences, for your next listen.

Browse charts by category

Daily updated Apple Podcasts rankings for the United States.

About BioSpace on Reason.fm

Here you find the Apple Podcasts chart positions of BioSpace, its latest episodes to listen to directly, and reviews from listeners. Rankings are updated daily for the United States.

Contact

Questions or issues? Reach us at hello@reason.fm

0:000:00